Ajanta Pharma
Ajanta Pharma Limited, headquartered in India, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of a diverse range of formulations. Founded in 1973, the company has established a strong presence in various operational regions, including Asia, Africa, and the Middle East. Ajanta Pharma is renowned for its focus on therapeutic areas such as ophthalmology, dermatology, and pain management, offering unique products that cater to specific medical needs. With a commitment to quality and innovation, the company has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. Recognised for its robust market position, Ajanta Pharma continues to expand its global footprint, driven by a dedication to enhancing patient care through effective and affordable healthcare solutions.
DitchCarbon Score
How does Ajanta Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ajanta Pharma's score of 24 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ajanta Pharma's reported carbon emissions
In 2023, Ajanta Pharma reported total carbon emissions of approximately 436,855 kg CO2e for Scope 1 and about 51,847,350 kg CO2e for Scope 2, resulting in a combined total of approximately 52,284,205 kg CO2e. This represents a slight decrease in Scope 1 emissions compared to 2022, where emissions were about 4,611,220 kg CO2e, while Scope 2 emissions increased from approximately 46,633,150 kg CO2e in the previous year. For 2024, Ajanta Pharma's emissions are projected to be approximately 6,390,220 kg CO2e for Scope 1 and about 40,007,740 kg CO2e for Scope 2, indicating a potential shift in their emissions profile. The company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, suggesting a need for further commitment in this area. Overall, Ajanta Pharma's emissions data highlights the importance of ongoing monitoring and potential strategies for emissions reduction, particularly in Scope 2, which constitutes the majority of their carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 3,660,360 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 41,756,300 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ajanta Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
